Researchers at Brigham and Women's Hospital in Boston are endeavoring to treat an aggressive brain cancer, glioblastoma, by appropriately utilizing a virus. The study was published in the Boston Herald, stating that the oncolytic virus treatment has effectively extended survival for patients with recurrent glioblastoma, particularly those with pre-existing viral antibodies.
Named CAN-3110, the oncolytic herpes simplex virus has demonstrated efficacy in infecting cancer cells and eliciting an anti-tumor immune response. In an unprecedented move, E. Antonio Chiocca, the Chair of the Department of Neurosurgery at BWH, indicates this virus has been particularly successful in increasing immune infiltration to the tumors, leading to a significant immune reaction and the infiltration of cancer-destroying T-cells.
The study, as disclosed by the Courant, detailed the initial trial of CAN-3110. The trial was designed to test the virus in terms of safety, drawing its roots from the virus used in metastatic melanoma treatment. In this study, 41 patients with high-grade gliomas, including 32 with recurrent glioblastomas, were involved to test the treatment's safety. Seizures encountered by two patients represented the worst adverse events.
More notably, patients with pre-existing HSV1 antibodies (66% of the studied group) survived for a median duration of 14.2 months. It's believed these HSV1 antibodies provoked a quick immune response upon virus introduction, thereby attracting more immune cells to the tumor site and inflaming the tumor microenvironment.
Glioblastoma treatment is particularly intricate due to the immunosuppressive conditions around the tumor that hinder the immune system's fight against it. Such conditions are on the brink of being transformed by this oncolytic virus treatment, from an "immune desert" into a pro-inflammatory environment.
As the project advances, the team of scientists is keen on conducting further studies. They aim to prove the overall efficiency of the virus amongst patients both with and without the HSV1 antibodies. Following the confirmed safety of a solitary viral injection, the experimentation will continue, with up to six injections planned for trial over a period of four months. By pursuing this approach that mimicks several rounds of vaccination, the treatment's efficacy could be raised significantly.
If proven successful, the CAN-3110 oncolytic virus could revolutionize glioblastoma treatment and potentially bring new hope to patients grappling with this aggressive brain cancer.
